T STEM -like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models
Science Translational Medicine · 05.04.2023 · 15 (690)
DOI: 10.1126/scitranslmed.abk1900 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 05.04.2023. Verfasst von Deborah Meyran und 28 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne 3000, Australia. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Neoplasms. Die Arbeit wurde bisher 109-mal zitiert (Crossref) und nennt 77 Literaturangaben.
Abstract (Originalsprache)
Patients who receive chimeric antigen receptor (CAR)–T cells that are enriched in memory T cells exhibit better disease control as a result of increased expansion and persistence of the CAR-T cells. Human memory T cells include stem-like CD8 + memory T cell progenitors that can become either functional stem-like T (T STEM ) cells or dysfunctional T progenitor exhausted (T PEX ) cells. To that end, we demonstrated that T STEM cells were less abundant in infused CAR-T cell products in a phase 1 clinical trial testing Lewis Y-CAR-T cells (NCT03851146), and the infused CAR-T cells displayed poor persistence in patients. To address this issue, we developed a production protocol to generate T STEM -like CAR-T cells enriched for expression of genes in cell replication pathways. Compared with conventional CAR-T cells, T STEM -like CAR-T cells had enhanced proliferative capacity and increased cytokine secretion after CAR stimulation, including after chronic CAR stimulation in vitro. These responses were dependent on the presence of CD4 + T cells during T STEM -like CAR-T cell production. Adoptive transfer of T STEM -like CAR-T cells induced better control of established tumors and resistance to tumor rechallenge in preclinical models. These more favorable outcomes were associated with increased persistence of T STEM -like CAR-T cells and an increased memory T cell pool. Last, T STEM -like CAR-T cells and anti–programmed cell death protein 1 (PD-1) treatment eradicated established tumors, and this was associated with increased tumor-infiltrating CD8 + CAR + T cells producing interferon-γ. In conclusion, our CAR-T cell protocol generated T STEM -like CAR-T cells with enhanced therapeutic efficacy, resulting in increased proliferative capacity and persistence in vivo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne 3000, Australia.
- Université de Paris, Inserm, U976 HIPI Unit, Institut de Recherche Saint-Louis, Paris F-75010, France.
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne 3010, Australia.
- Tumor Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Austin Health, Heidelberg, VIC 3084, Australia.
- School of Cancer Medicine, La Trobe University, Melbourne, VIC 3086, Australia.
- Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW 1466, Australia.
ORCID-Profile: Deborah Meyran, Joe Jiang Zhu, Daniela Tantalo, Thu Ngoc Nguyen, Minyu Wang, Niko Thio, Criselle D'Souza, Vicky Mengfei Qin, Clare Slaney, Kevin Sek, Kevin Thia, Andrew M Scott, Ben Tran, Jayesh Desai, H Miles Prince, Simon J Harrison, Paul A Beavis, Michael H Kershaw, Ben Solomon, Paul G Ekert, Joseph A Trapani, Phillip K Darcy, Paul J Neeson
Zitieren
APA
Meyran, D., Zhu, J. J., Butler, J., Tantalo, D., MacDonald, S., Nguyen, T. N., Wang, M., Thio, N., D'Souza, C., Qin, V. M., Slaney, C., Harrison, A., Sek, K., Petrone, P., Thia, K., Giuffrida, L., Scott, A. M., Terry, R. L., Tran, B., …, & Neeson, P. J. (2023). T STEM -like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models. Science Translational Medicine, 15(690). https://doi.org/10.1126/scitranslmed.abk1900
Vancouver
Meyran D, Zhu JJ, Butler J, Tantalo D, MacDonald S, Nguyen TN, et al. T STEM -like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models. Science Translational Medicine. 2023;15(690). doi:10.1126/scitranslmed.abk1900
BibTeX
@article{Meyran2023,
author = {Meyran, Deborah and Zhu, Joe Jiang and Butler, Jeanne and Tantalo, Daniela and MacDonald, Sean and Nguyen, Thu Ngoc and Wang, Minyu and Thio, Niko and D'Souza, Criselle and Qin, Vicky Mengfei and Slaney, Clare and Harrison, Aaron and Sek, Kevin and Petrone, Pasquale and Thia, Kevin and Giuffrida, Lauren and Scott, Andrew M and Terry, Rachael L and Tran, Ben and Desai, Jayesh and Prince, H Miles and Harrison, Simon J and Beavis, Paul A and Kershaw, Michael H and Solomon, Ben and Ekert, Paul G and Trapani, Joseph A and Darcy, Phillip K and Neeson, Paul J},
title = {T STEM -like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models},
journal = {Science Translational Medicine},
year = {2023},
volume = {15},
number = {690},
doi = {10.1126/scitranslmed.abk1900}
}
EUVIMED